Microdosing Tirzepatide: Doses, Chart, and What the Data Says
Microdosing tirzepatide means running a weekly dose below the approved 2.5 mg starter, usually 0.25 to 1.5 mg. People do it to dodge nausea, stretch supply, or hold a low maintenance dose. Here is the dose range, a week-by-week chart, the daily-versus-weekly question, and the honest limits of the evidence.
What Microdosing Tirzepatide Means
Tirzepatide is the dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. The approved schedule starts at 2.5 mg once weekly and climbs in steps to as much as 15 mg. Microdosing throws that ladder out and deliberately stays underneath it, typically in the 0.25 to 1.5 mg weekly range.
The label here matters less than the intent. A microdose is any amount chosen to be lower than the standard escalation calls for at that point, used either to ease into the drug gently or to sit at a low steady dose long term. For the full approved schedule, see the tirzepatide dosage chart.
Why People Microdose
The first reason is tolerance. The side effects of tirzepatide, nausea, vomiting, diarrhea, and constipation, cluster during dose increases. A slower, smaller approach gives the gut time to adapt and keeps people from quitting in the first month. Reducing the size of each step is the main lever you have over GI symptoms.
The second reason is cost and supply. Compounded tirzepatide is sold by the vial, and a smaller dose stretches that vial across more weeks. The third reason is maintenance: once someone hits a goal weight, a low dose can hold the result without the full ladder, an alternative to tapering off entirely.
Microdosing Tirzepatide Chart
There is no official microdosing chart because no trial studied these doses. The schedule below reflects what compounding clinics commonly use, not an FDA protocol. Treat it as a description of practice, not a recommendation to self-prescribe.
| Phase | Weekly dose | Typical duration | Goal |
|---|---|---|---|
| Entry | 0.25 mg | 2 to 4 weeks | Test tolerance, minimal GI effects |
| Low | 0.5 mg | 4+ weeks | Steady appetite suppression |
| Moderate | 1.0 mg | 4+ weeks | Stronger effect if loss stalls |
| Upper micro | 1.5 mg | Indefinite or bridge | Maintenance or step toward 2.5 mg |
The guiding principle in practice is to increase only when weight loss stalls and side effects are absent, rather than on a fixed calendar. Many people never leave the 0.5 to 1.5 mg band. Compare this with the standard approach in the tirzepatide dosage calculator.
Convert a Microdose to Units
The hardest part of microdosing is measurement. Small milligram amounts translate into very small volumes on an insulin syringe, and the exact units depend entirely on how the vial was reconstituted. Use the calculator to convert a target dose into syringe units, and read how to reconstitute peptides first so the concentration is right.
⚠️ Research purposes only. Not medical advice.
Always follow your prescribing physician's guidance. This calculator is educational and should not replace professional medical consultation.
Select Medication
Current Week
1
Current Dose
2.50mg
50.0 units on syringe
Next Refill
Week 4
4 doses per vial
Settings
Titration Schedule
| Week Range | Dose (mg) | Volume (units on 100U syringe) | Status |
|---|---|---|---|
| Weeks 1-4 | 2.50 | 50.0 units | ● CURRENT |
| Weeks 5-8 | 5.00 | 100.0 units | Upcoming |
| Weeks 9-12 | 7.50 | 150.0 units | Upcoming |
| Weeks 13-16 | 10.00 | 200.0 units | Upcoming |
| Weeks 17-20 | 12.50 | 250.0 units | Upcoming |
| Week 21+ | 15.00 | 300.0 units | Upcoming |
Vial Tracking
Total per Vial
10mg
Doses per Vial
4
at current dose
Weeks per Vial
4
Next refill: Week 4
This calculator provides estimates for educational purposes. Actual dosing and timing may vary based on individual medical needs and prescriber guidance.
Daily vs Weekly Microdosing
Tirzepatide has a half-life of roughly five days, which is why the drug was designed for once-weekly injection. Stable blood levels do not require daily dosing. Despite that, some protocols split a weekly amount into smaller daily injections, arguing that flatter peaks mean less nausea.
No controlled trial has compared daily microdosing against weekly at matched totals, so claims that one clearly beats the other are extrapolation. Weekly dosing is simpler, matches how the drug was studied, and means fewer needle sticks and fewer chances to misdose. Daily splitting multiplies the measurement-error problem described above. For technique, see injection technique and injection sites.
What the Evidence Does and Does Not Show
This is the part most microdosing content skips. The pivotal SURMOUNT-1 and SURMOUNT-2 trials tested tirzepatide at 5, 10, and 15 mg. The lowest dose ever formally evaluated is the 2.5 mg starter, and even that exists mainly to ease titration rather than as a therapeutic target. Everything below 2.5 mg is inferred from the shape of the dose-response curve, not measured.
That does not mean microdosing does nothing. A dose-dependent drug almost certainly has some effect below the studied range. But anyone claiming a specific weight-loss figure for 0.5 mg or 1 mg weekly is guessing. The reasonable expectation is slower loss with a gentler side-effect profile, with wide individual variation. For the full trial picture, see tirzepatide (Mounjaro) for weight loss.
Side Effects at Low Doses
Lower doses usually mean fewer and milder GI symptoms, which is the entire point. Nausea, the most common reason people stop, tends to track with dose size and the speed of escalation. Holding at a low dose lets the gut adapt.
Lower does not mean zero. People still report nausea, constipation, fatigue, and reflux at microdoses, and the serious warnings on the label, including the risk flagged for those with a history of medullary thyroid cancer, apply at any dose. Review long-term tirzepatide side effects and who should not take these drugs.
Supply, Compounding, and Legal Status
Microdosing is tied to vials, not pens. The branded Mounjaro and Zepbound autoinjectors deliver a fixed dose and cannot be dialed down, so microdosing runs almost entirely on compounded tirzepatide that comes in a vial you draw from.
That ties the practice to the compounding market, whose legal footing narrowed once the FDA shortage designation ended. Read is compounded tirzepatide safe, compounded tirzepatide, and our coverage of the FDA compounding crackdown. Research-grade tirzepatide bought online for self-injection is outside the legal supply chain and carries the quality risks covered in gray-market risks.
Who Microdosing Suits and Who It Does Not
Microdosing tends to appeal to people who are highly sensitive to GI side effects, who have a smaller amount of weight to lose, or who have already reached goal weight and want a low maintenance dose. It also draws people trying to make a costly supply last longer.
It is a poor fit for anyone who needs substantial weight loss on a timeline, since the studied doses exist for a reason, and for anyone tempted to improvise dosing without a clinician. The lack of trial data cuts both ways: gentler, but unproven. Compare the standard-dose path in semaglutide vs tirzepatide and the microdosing concept across the class in microdosing GLP-1.
Related Guides
Microdosing GLP-1
The microdosing concept applied across the whole GLP-1 class.
Tirzepatide Dosage Chart
The standard 2.5 to 15 mg weekly escalation schedule.
Compounded Tirzepatide Dosage
How vial-based compounded tirzepatide is dosed and measured.
Tirzepatide Side Effects
What to expect and how dose size changes the picture.
Tirzepatide (Mounjaro) Weight Loss
The trial data behind the standard doses.
Is Compounded Tirzepatide Safe?
Quality and sterility questions behind the vials.
Frequently Asked Questions About Microdosing Tirzepatide
Microdosing tirzepatide means using a weekly dose below the FDA-approved 2.5 mg starting dose, usually somewhere between 0.25 mg and 1.5 mg. The idea is to get appetite suppression and metabolic benefit while keeping the gastrointestinal side effects that drive most early quitting to a minimum. No randomized trial has ever tested tirzepatide below 2.5 mg, so the practice is extrapolated from the dose-response curve in SURMOUNT-1, not proven in its own right.
Most microdose protocols start at 0.25 to 0.5 mg per week and hold there as long as the person keeps losing weight and tolerating the drug. Some stay at 1 to 1.5 mg indefinitely as a maintenance dose rather than climbing to the standard 2.5 to 15 mg ladder. The defining feature is that the dose is deliberately kept under the approved 2.5 mg starter.
There is no trial evidence at sub-2.5 mg doses, so the honest answer is that it is plausible but unproven. Tirzepatide has a dose-dependent effect, and even the 2.5 mg starting dose produces some appetite suppression, so smaller amounts likely do something. People who microdose often report slower but steadier loss with fewer side effects. What is missing is controlled data showing how much weight a 0.5 mg or 1 mg weekly dose produces over a year.
Three main reasons: to reduce nausea, vomiting, constipation, and other GI effects that peak during dose escalation; to stretch a limited or expensive supply of compounded tirzepatide further; and to stay on a low maintenance dose after reaching a goal weight rather than tapering off entirely. For some people the standard titration is simply intolerable, and a smaller dose is the difference between staying on the drug and quitting.
Tirzepatide has a half-life of about five days, so it does not require daily dosing to maintain stable levels. Some protocols still split a weekly amount into smaller daily injections on the theory that flatter peaks mean less nausea. There is no head-to-head trial proving daily microdosing beats weekly. Weekly dosing matches how the drug was studied and is simpler. Daily dosing means more injections and more room for error.
Lower doses generally mean fewer and milder side effects, but microdosing is not inherently safer in every sense. Most microdosing uses compounded or gray-market tirzepatide drawn from multi-dose vials, which introduces risks around sterility, dosing accuracy, and product purity that branded pens do not have. The contraindications for tirzepatide still apply at any dose, including a personal or family history of medullary thyroid cancer or MEN 2. Microdosing should be done under medical supervision, not improvised.
Microdoses are small volumes, which makes measurement error a real problem. Accurate dosing depends on knowing the exact concentration after reconstitution and using an appropriately sized insulin syringe. A reconstitution calculator helps convert a target milligram dose into units on the syringe. Getting the concentration math wrong is one of the most common ways people end up taking far more or far less than they intend.
The branded pens (Mounjaro and Zepbound) are fixed-dose autoinjectors that deliver a preset amount and cannot be dialed down, so they do not lend themselves to microdosing. Microdosing is almost always done with compounded tirzepatide supplied in vials, which can be drawn up in custom amounts. That is also why microdosing is tied to the compounding market and its specific legal and quality questions.
Tirzepatide itself is a prescription drug. Microdosing is an off-label way of using it, and off-label prescribing is legal when done by a licensed clinician. The complication is supply: most microdosing relies on compounded tirzepatide, whose legal status has tightened as the FDA shortage designation ended. Buying research-grade tirzepatide online for self-injection sits outside the legal and quality-controlled supply chain entirely.